Edwards Lifesciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EW and other ETFs, options, and stocks.

About EW

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. 

CEO
Bernard J. Zovighian
CEOBernard J. Zovighian
Employees
15,800
Employees15,800
Headquarters
Irvine, California
HeadquartersIrvine, California
Founded
1958
Founded1958
Employees
15,800
Employees15,800

EW Key Statistics

Market cap
49.43B
Market cap49.43B
Price-Earnings ratio
35.79
Price-Earnings ratio35.79
Dividend yield
Dividend yield
Average volume
5.09M
Average volume5.09M
High today
$85.40
High today$85.40
Low today
$84.08
Low today$84.08
Open price
$84.51
Open price$84.51
Volume
2.64M
Volume2.64M
52 Week high
$87.09
52 Week high$87.09
52 Week low
$64.89
52 Week low$64.89

Stock Snapshot

The current Edwards Lifesciences(EW) stock price is $85.16, with a market capitalization of 49.43B. The stock trades at a price-to-earnings (P/E) ratio of 35.79.

During the trading session on 2025-11-11, Edwards Lifesciences(EW) shares reached a daily high of $85.40 and a low of $84.08. At a current price of $85.16, the stock is +1.3% higher than the low and still -0.3% under the high.

Trading activity shows a volume of 2.64M, compared to an average daily volume of 5.09M.

Over the past 52 weeks, Edwards Lifesciences(EW) stock has traded between a high of $87.09 and a low of $64.89.

Over the past 52 weeks, Edwards Lifesciences(EW) stock has traded between a high of $87.09 and a low of $64.89.

EW News

Simply Wall St 2d
Edwards Lifesciences: Exploring Current Valuation After Recent Gains and Innovation Momentum

Edwards Lifesciences (EW) has caught investors’ attention this month as its stock continues to climb, building on several weeks of gains. The company’s momentum...

Edwards Lifesciences: Exploring Current Valuation After Recent Gains and Innovation Momentum
Simply Wall St 6d
How Strong Clinical Data and Upbeat Guidance at Edwards Lifesciences Have Changed Its Investment Story

In the past week, Edwards Lifesciences reported third quarter results with US$1.55 billion in sales, raised its full-year sales growth guidance, announced a tra...

How Strong Clinical Data and Upbeat Guidance at Edwards Lifesciences Have Changed Its Investment Story

Analyst ratings

60%

of 35 ratings
Buy
60%
Hold
40%
Sell
0%

People also own

Based on the portfolios of people who own EW. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.